Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126157 | 0.87 | IDO1 (0.61) | IDO1FOLH1CYP1A2 | |
| SCHEMBL166894 | 0.87 | TP53 (0.61) | IDO1TP53CYP1A2CYP2A6MGLL | |
| SCHEMBL28256639 | 0.84 | TP53 (0.58) | IDO1TP53CYP1A2CYP2A6MGLL | |
| Ammonia Solution, Strong SCHEMBL28805948 | 0.84 | TP53 (0.58) | IDO1TP53CYP1A2CYP2A6MGLL | |
| Benzene SCHEMBL9785236 | 0.84 | TP53 (0.67) | IDO1TP53CYP1A2CYP2A6MGLL | |
| Methyl Alcohol SCHEMBL28745884 | 0.81 | TP53 (0.55) | IDO1TP53CYP1A2CYP2A6MGLL | |
| Ethyne SCHEMBL28293458 | 0.81 | TP53 (0.55) | IDO1TP53CYP1A2CYP2A6MGLL | |
| SCHEMBL8144688 | 0.81 | IDO1 (0.63) | IDO1FOLH1CYP1A2 | |
| Hydrogen Peroxide SCHEMBL11520377 | 0.81 | TP53 (0.63) | TP53CYP1A2CYP2A6MGLLBCL2 | |
| Ethylene SCHEMBL27256792 | 0.81 | TP53 (0.55) | IDO1TP53CYP1A2CYP2A6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6225370-B1 | FOR USE WITH INK JET PRINTERS | LEXMARK INTERNATIONAL, INC. | 2001-05-01 | — | — | US | claimed |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | IMMUNOGEN, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814445-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL SA (ES) | 2020-08-13 | — | — | US | disclosed |
| EP-1951815-B1 | FLAME RESISTANT POLYMER BLENDS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2017-05-24 | — | — | EP | disclosed |
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-6225370-B1 | FOR USE WITH INK JET PRINTERS | LEXMARK INTERNATIONAL, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5455355-A | Postemergence, preemergence herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-10-03 | — | — | US | disclosed |
| EP-0468690-B1 | Pyrimidine derivatives | SUMITOMO CHEMICAL CO (JP) | 1995-05-31 | — | — | EP | disclosed |
| US-5298632-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5232897-A | Herbicidal pyrimidine compounds, compositions containing the same and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0549344-A1 | Triazine derivatives as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-06-30 | — | — | EP | disclosed |
| US-5135563-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-08-04 | — | — | US | disclosed |
| US-5129938-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0469711-A1 | Pyrimidine derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-02-05 | — | — | EP | disclosed |
| EP-0468690-A1 | Pyrimidine derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0457505-A2 | Pyrimidine derivatives and their use as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | IDO1 564/4885TP53 2364/4885FOLH1 374/4885 |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | EPCAM, CD2BP2, XPA | IDO1 4364/4885TP53 376/4885FOLH1 150/4885 |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | IDO1 4049/4885TP53 3599/4885FOLH1 984/4885 |
| US-11814445-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | IDO1 4049/4885TP53 3599/4885FOLH1 984/4885 |
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | KEAP1, NFE2L2, HMOX1 | IDO1 1326/4885TP53 652/4885FOLH1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.